Cork's NeuroBell secures €5m in new funding for US launch

UCC spin-out's device detects seizures in newborns

Colm Murphy, CTO, NeuroBell, Olive O'Driscoll, Chairperson, NeuroBell, Dr Alison O'Shea, CSO, NeuroBell, Dara O'Shea, Senior Investment Associate, Elkstone and Dr Mark O'Sullivan, CEO.

Cork medical technology company NeuroBell has secured $5.5m (€4.8m) in investment to accelerate the launch of its LUNA neonatal brain monitor in the US.

NeuroBell, co-founded by Dr Mark O’Sullivan, Dr Alison O’Shea and Colm Murphy, spun out from University College Cork in 2023, after nearly a decade of academic research into newborn brain health. 

The LUNA device can help identify seizures in newborns, which often produce no visible symptoms, but delays in detection and treatment multiply the risk of long-term brain damage.

The new funding round was led by Elkstone, with participation from the US health system, Parkview Health, and alongside existing investors Furthr VC, Atlantic Bridge, Medtech Syndicate and Enterprise Ireland.

LUNA is a pocket-sized and wireless EEG device designed for ease of use in neonatal intensive care units (NICU), enabling clinical staff to detect seizures at the bedside with AI-assisted analysis and remote reviewing capability. The device underwent a successful clinical investigation at Cork University Maternity Hospital (CUMH) in 2025, demonstrating high correlation with conventional brain monitors and a significant reduction in false alerts compared to existing solutions.

"LUNA exists to put clinical-grade brain monitoring in the hands of every NICU team, wherever they are," Dr Mark O’Sullivan, CEO of NeuroBell, said. "This investment gives us the resources to scale that vision to patients in the US and across Europe.” The new funding supports the company as it prepares for US Food & Drug Administration clearance, a milestone anticipated in the coming months. 

Niall McEvoy, Head of Venture at Elkstone, said: “NeuroBell addresses a problem that is both urgent and underserved. Neonatal seizures are largely silent, and the current standard of care leaves too many NICUs without the tools to detect them reliably. The team have spent nearly a decade solving this with rigorous science and world-class engineering. We are delighted to lead this round and support Mark, Alison, Colm and the team as they prepare for FDA clearance and US market entry.” 

The investment by Parkview Health, a US health system operating 15 hospitals with more than 17,500 staff, strengthens an existing clinical partnership and is expected to accelerate NeuroBell’s market access in the US, supported by the company’s newly established office in Fort Wayne, Indiana

“Every newborn deserves the safest possible start to life,” said Dr Atiya Khan, pediatric neurologist, Parkview Health. “We are committed to bringing innovations to the bedside that help us detect and respond to conditions like seizures as early as possible.